Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc. (TSHA) Stock Ticker

NASDAQ: TSHA · Healthcare · Biotechnology
$4.67-2.51%
USD · as of 2026-09-28 · market cap $1.5B
Open TSHA in TickrDownload for iPhone

TSHA right now

Options expect by Oct 6±8.3%
Options expect by Oct 29±17.3%
Priced in for Nov 3 earnings±18.6%
IV rank (30-day)47% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full TSHA picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on TSHA
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.

TSHA stock facts

Ticker symbolTSHA
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$1.5B
CEOSean Nolan
Employees99
HeadquartersDallas, TX, US
IPO date2020-09-24
Websitewww.tayshagtx.com

What you can see for TSHA on Tickr

Live TSHA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the TSHA report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Taysha Gene Therapies, Inc.?

The ticker symbol for Taysha Gene Therapies, Inc. is TSHA, listed on the NASDAQ Global Select.

What is TSHA?

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in…

HomeExploreMarketLists
All pages